English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma

MPS-Authors
/persons/resource/persons278011

Jachimowicz,  R. D.
Jachimowicz – Mechanisms of DNA Repair, Max Planck Research Groups, Max Planck Institute for Biology of Ageing, Max Planck Society;

External Resource

https://www.ncbi.nlm.nih.gov/pubmed/23225085
(Any fulltext)

Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Sauer, M., Plutschow, A., Jachimowicz, R. D., Kleefisch, D., Reiners, K. S., Ponader, S., et al. (2012). Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol, 88(2), 113-5. doi:10.1002/ajh.23361.


Cite as: https://hdl.handle.net/21.11116/0000-000B-7234-A
Abstract
Hodgkin lymphoma (HL) has become one of the best curable cancers. However, better biomarkers are needed for outcome prediction that would allow protecting patients from over- or under-dosing of treatment. Thymus and activation-regulated chemokine/CCL17 (TARC) is highly and specifically elevated in this disease and has been proposed as possible biomarker in HL patients. In this study, we show that pretreatment TARC levels were associated with established clinical risk factors and predictive for response to treatment in a large cohort of HL patients treated in clinical trials by the German Hodgkin Study Group. Moreover, TARC levels also significantly contributed to a novel multivariate model predicting treatment response. These data clearly suggest an important role for this chemokine as biomarker in HL.